Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
GlobeNewswire
*Media Release*
*COPENHAGEN, Denmark; June 2, 2024*
· *Preliminary analysis of data from the **EPCORE™..